New drug may soothe immunotherapy skin rash without hurting cancer fight
Symptom relief
Not yet recruiting
This study tests a JAK inhibitor drug for cancer patients who develop severe skin rashes from immunotherapy. The goal is to relieve the rash quickly without weakening the cancer treatment. About 35 adults with hard-to-treat rashes will take the drug and be monitored for side effe…
Phase: PHASE2 • Sponsor: Shixiu Wu • Aim: Symptom relief
Last updated May 03, 2026 12:30 UTC